Keiretsu Capital

Home
United States
Seattle, WA
Keiretsu Capital

Keiretsu Capital administers funds on behalf of its Limited Partners - the Co-Investment & Opportunities Fund creates a diversified portfolio of companies.

06/15/2026

Archax is addressing a critical bottleneck in the digital asset market by partnering with financial infrastructure provider OpenPayd to streamline multi-currency fiat settlement. As institutional participation grows, optimizing the interface between traditional and digital finance is vital for systemic efficiency and scale.

Through this integration, the company will leverage regulated financial infrastructure to facilitate instant GBP, EUR, and USD fiat settlements across its global trading operations. By creating a unified and compliant treasury environment, the collaboration eliminates traditional operational friction, shortens settlement cycles with institutional liquidity partners, and accelerates reconciliation workflows.

Read more: https://archax.com/insights/archax-and-openpayd-partner-to-streamline-multi-currency-settlement-for-digital-asset-trading

06/01/2026

Inmedix has been named one of F**t Insider’s 50 most interesting early-stage health and wellness startups, recognizing its FDA-cleared platform that helps clinicians personalize care by measuring stress-immune responses in autoimmune disease. Read more: https://tinyurl.com/mscf7723

05/25/2026

NuvOx Therapeutics is advancing care for life-threatening hypoxemic conditions. Its EXTEND-1b Phase Ib trial for NanO₂™ showed improved oxygenation with dose escalation while maintaining a strong safety profile.

Read more: https://tinyurl.com/5darxw65

05/18/2026

Viakoo has announced a strategic collaboration with Siemens to deliver advanced OT/IoT security management solutions.

Through this partnership, Siemens will integrate the Viakoo Action Platform into its offerings, enabling enterprises to automate device management, proactively detect vulnerabilities, and maintain real-time compliance across large-scale connected environments.

Read more: https://www.viakoo.com/blog/newsroom_detail/siemens-and-viakoo-collaborate/

05/11/2026

Another Tomorrow is redefining responsibility and ownership in modern luxury.
Founder and Co-CEO Vanessa Barboni Hallik highlights the role of the Digital Product Passport as critical infrastructure in enabling transparency, circularity, and regenerative practices. By embedding verified, data-driven insights across the value chain, the brand is able to communicate its full story from sourcing to impact with credibility and precision.
Read more: https://www.linkedin.com/posts/luxury-shapers-another-tomorrow-ugcPost-7424405095510974465-tMTT/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAABlxnUBBr7irsJMED9HopgaoXoLQwaVNdc

05/04/2026

CrossTX has been successfully acquired by The Wellness Group, marking a significant milestone in its growth journey.
Rebranded as Wellgineering, the company will play a key role in advancing a $250M investment initiative focused on building a vertically integrated ecosystem across personalized health, precision therapeutics, and connected care.
Read More: https://tinyurl.com/5fmj9pe9

04/27/2026

Virion Therapeutics reports that a single dose of its drug VRON-0200 triggered strong and lasting immune responses against hepatitis B in most chronically infected patients in its Phase 1b study.

Read more: https://www.businesswire.com/news/home/20260222314451/en/Virion-Therapeutics-Reports-Broad-and-Sustained-Anti-HBV-Immunity-Following-a-Single-VRON-0200-Dose-in-the-Majority-of-Chronically-HBV-Infected-Patients-From-its-Phase-1b-Study-at-CROI-2026

04/20/2026

Lungpacer achieves a key commercial milestone as a leading U.S. hospital completes the first AeroPace procedures.

This marks the real-world launch of its FDA-approved transvenous diaphragm neurostimulation system designed to help critically ill, ventilated patients regain independent breathing faster, reduce time on mechanical ventilation, and improve ICU recovery outcomes.

Read more: https://lungpacer.com/lungpacer-achieves-commercial-milestone-as-leading-u-s-hospital-performs-first-aeropace-procedures-to-help-patients-liberate-from-mechanical-ventilation/

04/13/2026

Archax partners with ClearBid Global Markets to support its expansion into the UK and EU, enabling a regulated digital bond trading and data platform that improves transparency, enhances price discovery, and expands institutional access across infrastructure, corporate, and asset-backed markets.
Read More: https://archax.com/insights/clearbid-global-markets-selects-archax-as-partner-for-uk-and-eu-expansion

04/06/2026

Nuvox Therapeutics has received FDA approval to start its Phase II REBORN trial of NanO₂ for recurrent high‑grade glioma. The trial will test if NanO₂ can help tumors respond better to treatment and improve outcomes for patients facing this aggressive form of brain cancer.
Read more: https://tinyurl.com/ms2x9tkv

Address

2815 Eastlake Avenue East, Suite 300
Seattle, WA
98102

Telephone

+12062558870

Website

http://www.keiretsucapital.com/

Alerts

Be the first to know and let us send you an email when Keiretsu Capital posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Keiretsu Capital:

Shortcuts

Want your business to be the top-listed Finance Company in Seattle?